Biểu đồ giá cổ phiếu 03378.HK
HANXBIO-B (03378.HK)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
HK$32.2
2.87%
$0.9
Thị trường đóng cửa: May 08, 16:00:00 HKT
Quay lại
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK)
Thống kê chính
Giá đóng cửa trước
$31.3
Giá mở cửa
$31.3
Phạm vi ngày
$30.9 - $32.8
Phạm vi 52 tuần
$13.48 - $32.94
Khối lượng
109.4K
Khối lượng trung bình
143.5K
Tỷ suất cổ tức
--
EPS (TTM)
-1.27
Vốn hóa thị trường
$4.3B
HANXBIO-B là gì?
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. engages in the research and development of immuno-oncology therapies. The company is headquartered in Wuhan, Hubei. The company went IPO on 2025-12-23. The Company’s core products include HX009, HX301, HX044, and HX008. HX009 is a bifunctional anti-PD-1 antibody SIRP fusion protein, aiming at enhancing PD-1 function and creating a PD-1 molecule. HX301 is a multi-targeted kinase inhibitor with a unique kinase inhibition profile. HX044 is a clinical-stage drug for treatment of various types of malignancies, particularly PD-1-resistant solid tumors. HX008 is a humanized antagonist mAb against human PD-1 by using human IgG4 isotype, which can inhibit the PD-1 signal to restore the capability of the immune cells to kill cancer cells through blocking PD-1 binding to their ligands PD-L1 and PD-L2.
